JP2004511201A - ナイセリアゲノム配列およびそれらの使用方法 - Google Patents

ナイセリアゲノム配列およびそれらの使用方法 Download PDF

Info

Publication number
JP2004511201A
JP2004511201A JP2000576277A JP2000576277A JP2004511201A JP 2004511201 A JP2004511201 A JP 2004511201A JP 2000576277 A JP2000576277 A JP 2000576277A JP 2000576277 A JP2000576277 A JP 2000576277A JP 2004511201 A JP2004511201 A JP 2004511201A
Authority
JP
Japan
Prior art keywords
protein
sequence
seq
meningitidis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000576277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511201A5 (enExample
Inventor
フレイザー，　クレール　エム．
ヒッキー，　エリン
ピーターソン，　ジェレミー
テテリン，　ハーブ
ヴェンター，　ジェイ．　クレイグ
マシナーニ，　ヴェガ
ギャレオッティ，　セシラ
モラ，　マリロサ
ラッティ，　ギウリオ
スカーセリ，　マリア
スカーラト，　ビンセンツォ
ラップオリ，　リノ
ピッツァ，　マリアグラティア
グランディー，　グイド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Genomic Research
Original Assignee
Institute for Genomic Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Genomic Research filed Critical Institute for Genomic Research
Publication of JP2004511201A publication Critical patent/JP2004511201A/ja
Publication of JP2004511201A5 publication Critical patent/JP2004511201A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000576277A 1998-10-09 1999-10-08 ナイセリアゲノム配列およびそれらの使用方法 Pending JP2004511201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10379498P 1998-10-09 1998-10-09
US13206899P 1999-04-30 1999-04-30
PCT/US1999/023573 WO2000022430A2 (en) 1998-10-09 1999-10-08 Neisseria genomic sequences and methods of their use

Publications (2)

Publication Number Publication Date
JP2004511201A true JP2004511201A (ja) 2004-04-15
JP2004511201A5 JP2004511201A5 (enExample) 2006-11-24

Family

ID=26800862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000576277A Pending JP2004511201A (ja) 1998-10-09 1999-10-08 ナイセリアゲノム配列およびそれらの使用方法

Country Status (10)

Country Link
US (1) US7612192B2 (enExample)
EP (2) EP1144998A3 (enExample)
JP (1) JP2004511201A (enExample)
CN (1) CN1338005A (enExample)
AU (1) AU1202200A (enExample)
BR (1) BR9914374A (enExample)
CA (1) CA2346713A1 (enExample)
MX (1) MXPA01003557A (enExample)
NZ (1) NZ511540A (enExample)
WO (1) WO2000022430A2 (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
JPH10502365A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
EP0909323B1 (en) * 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ATE446368T1 (de) * 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
WO2000034482A2 (en) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Novel compounds derived from neisseria meningitidis
AU2109700A (en) 1999-01-22 2000-08-07 Smithkline Beecham Biologicals (Sa) Novel compounds
US7666988B1 (en) 1999-03-12 2010-02-23 Glaxosmithkline Biologicals S.A. BASB082 Polypeptides
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
ES2323845T3 (es) * 1999-04-30 2009-07-27 Novartis Vaccines And Diagnostics, Inc. Secuencias genomicas de neisseria y procedimientos de uso.
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
AU2003271337B2 (en) * 1999-08-03 2005-07-21 Smithkline Beecham Biologicals S.A. Vaccine composition
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE460484T1 (de) * 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) * 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0020952D0 (en) * 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
AU2002219032A1 (en) * 2000-09-09 2002-03-26 Degussa A.G. Nucleotide sequences which code for the dep34 gene
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
NZ532274A (en) * 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
JP4646516B2 (ja) 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
AU2003239125A1 (en) 2002-03-20 2003-10-08 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220205D0 (en) 2002-08-30 2002-10-09 Chiron Spa Neisseria toxin
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
AU2007263531B2 (en) 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
CA2758687A1 (en) 2008-11-14 2010-05-20 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
EP2723378A4 (en) 2011-06-24 2015-01-28 Epitogenesis Inc PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF VECTORS, VITAMINS, TANNINS AND FLAVONOIDS SELECTED AS ANTIGEN-SPECIFIC IMMUNOMODULATORS
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
CN104582718B (zh) 2012-10-03 2017-10-24 诺华股份有限公司 免疫原性组合物
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
WO2019075053A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. PORCINE G-CSF VARIANTS AND USES THEREOF
CN109161546B (zh) * 2018-09-20 2021-11-09 广西科学院 一种核酸适配体及其在检测卵形鲳鲹源致病性溶藻弧菌中的应用
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0467714A1 (en) * 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
WO1998017805A2 (en) * 1996-10-24 1998-04-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office Invasion associated genes from neisseria meningitidis serogroup b

Also Published As

Publication number Publication date
WO2000022430A3 (en) 2002-06-06
US7612192B2 (en) 2009-11-03
MXPA01003557A (es) 2004-04-05
WO2000022430A2 (en) 2000-04-20
BR9914374A (pt) 2002-09-17
CA2346713A1 (en) 2000-04-20
US20050191316A1 (en) 2005-09-01
WO2000022430A9 (en) 2002-07-04
CN1338005A (zh) 2002-02-27
NZ511540A (en) 2004-05-28
EP1559795A2 (en) 2005-08-03
EP1144998A3 (en) 2002-08-07
EP1144998A2 (en) 2001-10-17
EP1559795A3 (en) 2005-11-09
AU1202200A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
JP5102414B2 (ja) 髄膜炎菌抗原および組成物
EP1185691B1 (en) Neisseria genomic sequences and methods of their use
JP4399112B2 (ja) ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
EP1559795A2 (en) Neisseria genomic sequences and methods of their use
US20070026021A1 (en) Neisseria meningitidis antigens and compositions
RU2232191C2 (ru) Белок, соответствующий антигенному белку neisseria meningitidis и обладающий иммуногенными свойствами (варианты), связывающееся с ним антитело, нуклеотидная последовательность (варианты) и содержащая их фармацевтическая композиция
AU2012203235B2 (en) Neisseria meningitidis antigens and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090716

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091019